INM: InMed Pharmaceuticals Inc. Stock

by  •  • Comments Off on INM: InMed Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.67
Enterprise Value ($M) -5.93
Book Value ($M) 11.10
Book Value / Share 1.83
Price / Book 0.15
NCAV ($M) 7.81
NCAV / Share 1.29
Price / NCAV 0.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.41
Return on Equity (ROE) -0.49

Liquidity (mrq)
Quick Ratio 5.80
Current Ratio 6.58

Balance Sheet (mrq) ($M)
Current Assets 10.06
Assets 13.36
Liabilities 2.25
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 9.99
01-04 13G Sabby Management, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT
2023-12-21 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITI
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-09-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-17 607,710 1,459,828 41.63
2024-05-16 110,434 15,075 732.56
2024-05-15 37,261 98,190 37.95
2024-05-14 22,516 67,507 33.35
2024-05-13 11,183 195,045 5.73

(click for more detail)

Similar Companies
IMTX – Immatics N.V. INDP – Indaptus Therapeutics, Inc.
INKT – MiNK Therapeutics, Inc. INMB – INmune Bio, Inc.
INTS – Intensity Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io